Metformin Hydrochloride Milpharm (Metformin Hydrochloride)

• Metformin Hydrochloride is an oral antidiabetic agent used primarily in the treatment of disorders characterized by elevated blood glucose.
• Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose production and enhancing peripheral insulin sensitivity.
• Prediabetes (impaired fasting glucose): helps delay progression to type 2 diabetes when combined with lifestyle modification.

• Metformin Hydrochloride acts by inhibiting mitochondrial respiratory-chain complex I, which reduces hepatic gluconeogenesis and decreases intestinal glucose absorption. It also increases peripheral glucose uptake and utilization by enhancing insulin receptor tyrosine kinase activity, thereby improving insulin sensitivity without stimulating insulin secretion.

Metformin Hydrochloride may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects

• Nausea: mild to moderate stomach upset occurring early in therapy.
• Diarrhoea: loose stools that may improve with dose titration.
• Abdominal discomfort: cramping or bloating often transient.
• Metallic taste: transient alteration in taste perception.
• Loss of appetite: reduced desire to eat, usually mild.
• Vitamin B12 deficiency: gradual decrease with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening accumulation of lactate, especially in renal impairment.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic failure: marked liver dysfunction leading to elevated enzymes and jaundice.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• Hypoglycaemia (when combined with other antidiabetics): unusually low blood glucose levels.

• When prescribing Metformin Hydrochloride, clinicians should observe the following precautions to minimise risk.
• Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter.
• Hepatic function monitoring: avoid use in patients with severe liver disease.
• Risk of lactic acidosis: discontinue if patient develops hypoxia, sepsis, or acute heart failure.
• Vitamin B12 levels: monitor during long‑term therapy as deficiency may occur.
• Pregnancy and lactation: assess benefits versus risks; use only if clearly needed.
• Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Metformin Hydrochloride can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk.
• Alcohol: potentiates risk of lactic acidosis and hypoglycaemia.
• Cimetidine: can raise plasma metformin concentrations.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may affect renal function, requiring dose adjustment.
• Beta‑blockers: can mask hypoglycaemia symptoms.
• Diuretics (especially thiazides): may increase risk of renal impairment.
• Warfarin: may alter INR, necessitating closer monitoring.
• Sulfonylureas: additive hypoglycaemic effect, requiring dose titration.